德国拜耳利伐沙班药品说明书

In 1997, Bayer Healthcare entered the Chinese pharmaceutical market and developed prescription drugs, over-the-counter drugs, medical diagnostics, and animal health services. In 2005, Bayer Healthcare achieved sales revenue of €9.4 billion. It is a targeted drug developed and produced by Bayer for the treatment of venous thrombosis.

Generic name: Rivaroxaban

Product name: Xarelto

Full names: Rivaroxaban, Xarelto

Indications:

Mainly used to treat venous thrombosis in adults.

For the prevention of venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery.

It is used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT.

For use in adult patients with non-valvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism.

Usage and dosage:

Take orally.

Rivaroxaban 10mg can be taken with food or alone.

Rivaroxaban 15 mg or 20 mg tablets should be taken with food.

Prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery.

The recommended dose is rivaroxaban 10 mg orally once daily. If the wound has stopped bleeding, the first dose of medication should be between 6 and 10 hours after surgery.

For patients undergoing major hip surgery, the recommended course of treatment is 35 days.

For patients undergoing major knee surgery, the recommended course of treatment is 12 days.

If a missed dose occurs, patients should take Xarelto immediately and continue taking the dose once daily the next day.

Treat DVT (venous thrombosis) and reduce the risk of acute DVT recurrence and PE

The recommended dose for initial treatment of acute DVT is 15 mg twice daily for the first three weeks, followed by 20 mg once daily for maintenance treatment and to reduce the risk of recurrent DVT and PE.

For use in adult patients with non-valvular atrial fibrillation to reduce the risk of stroke and systemic embolism

The recommended dose is 20 mg once a day, which is also the maximum recommended dose. For patients with low body weight and advanced age (>75 years old), doctors can use 15 mg once a day as appropriate based on the patient's condition.

Taboo:

Severe allergy to rivaroxaban or any of its ingredients;

Patients with clinically apparent active bleeding;

Patients with liver disease who are at risk for coagulation abnormalities and clinically relevant bleeding;

Not suitable for pregnant and lactating women.

Recommended related hot articles: /newsDetail/90159.html